Clinical Trials

Find trials by condition, location & phase

Drug Monographs

Browse drug monographs and information

Explore organizations and their profiles

Latest updates on trials and healthcare

Approved products by global authorities

AI-Powered Research

Discover powerful insights with advanced AI analysis tools for clinical trials.

Premium Access

Get unlimited access to our comprehensive pharmaceutical database and analytics.

NATIONAL INSTITUTES OF HEALTH

🇺🇸United States

Country: 🇺🇸United States

Ownership: Subsidiary, Private

Established: 1948-01-01

Employees: 1K

Market Cap: -

Website: http://www.nidcr.nih.gov

Clinical Trials

Carboplatin and Paclitaxel With or Without Bevacizumab Compared to Docetaxel, Carboplatin, and Paclitaxel in Treating Patients With Stage II, Stage III, or Stage IV Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cavity Carcinoma (Cancer)

Phase 1

Completed

Conditions: Ovarian Serous Cystadenocarcinoma
Primary Peritoneal Cavity Cancer
Fallopian Tube Cancer
Ovarian Mucinous Cystadenocarcinoma
Stage III Ovarian Epithelial Cancer
Ovarian Undifferentiated Adenocarcinoma
Stage IV Ovarian Epithelial Cancer
Brenner Tumor
Ovarian Carcinosarcoma
Ovarian Clear Cell Cystadenocarcinoma

Interventions: Drug: carboplatin
Drug: paclitaxel
Drug: docetaxel
Biological: bevacizumab

First Posted Date: 2004-06-11

Last Posted Date: 2019-07-22

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 40

Registration Number: NCT00085358

Locations: 🇺🇸
Gynecologic Oncology Group, Philadelphia, Pennsylvania, United States
🇺🇸
Washington University School of Medicine, Saint Louis, Missouri, United States
🇺🇸
Cancer Care Associates-Yale, Tulsa, Oklahoma, United States

and more 13 locations

Phase II Study of Oxaliplatin, Irinotecan, and Capecitabine in Advanced Gastric/Gastroesophageal Junction Carcinoma

Phase 2

Completed

Conditions: Diffuse Adenocarcinoma of the Stomach
Stage IIIB Gastric Cancer
Adenocarcinoma of the Gastroesophageal Junction
Stage IIIC Gastric Cancer
Recurrent Gastric Cancer
Stage IV Gastric Cancer
Intestinal Adenocarcinoma of the Stomach
Mixed Adenocarcinoma of the Stomach
Stage IIIA Gastric Cancer

Interventions: Drug: oxaliplatin
Drug: irinotecan hydrochloride
Drug: capecitabine

First Posted Date: 2004-06-11

Last Posted Date: 2015-05-01

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 39

Registration Number: NCT00084617

Locations: 🇺🇸
Case Western Reserve University, Cleveland, Ohio, United States

Topotecan and Radiation Therapy in Treating Patients With Solid Tumors or Lymphoma

Phase 1

Completed

Conditions: Esophageal Cancer
Lung Cancer
Lymphoma

Interventions: Drug: topotecan hydrochloride
Radiation: low-LET electron therapy
Radiation: low-LET photon therapy

First Posted Date: 2004-06-10

Last Posted Date: 2013-02-11

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 5

Registration Number: NCT00002625

Locations: 🇺🇸
University of Wisconsin Comprehensive Cancer Center, Madison, Wisconsin, United States

Chemotherapy Plus Monoclonal Antibody Therapy in Treating Women With Stage II or Stage IIIA Breast Cancer That Overexpresses HER2

Phase 2

Completed

Conditions: Breast Cancer

Interventions: Biological: trastuzumab
Drug: cyclophosphamide
Drug: doxorubicin hydrochloride
Drug: paclitaxel
Drug: tamoxifen citrate

First Posted Date: 2004-06-09

Last Posted Date: 2013-06-03

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 200

Registration Number: NCT00003992

Locations: 🇺🇸
Robert H. Lurie Comprehensive Cancer Center, Northwestern University, Chicago, Illinois, United States
🇺🇸
Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States
🇺🇸
CCOP - Kalamazoo, Kalamazoo, Michigan, United States

and more 42 locations

Lung Screening Study

Not Applicable

Completed

Conditions: Lung Cancer

First Posted Date: 2004-06-09

Last Posted Date: 2015-05-05

Lead Sponsor: National Cancer Institute (NCI)

Registration Number: NCT00006382

Locations: 🇺🇸
University of Alabama Comprehensive Cancer Center, Birmingham, Alabama, United States
🇺🇸
Vincent T. Lombardi Cancer Research Center, Georgetown University, Washington, District of Columbia, United States
🇺🇸
Henry Ford Hospital, Detroit, Michigan, United States

and more 3 locations

Carboxyamidotriazole + RT in Treating Patients Newly Diagnosed Supratentorial GBM

Phase 2

Completed

Conditions: Adult Giant Cell Glioblastoma
Adult Glioblastoma
Adult Gliosarcoma

Interventions: Radiation: radiation therapy
Drug: carboxyamidotriazole
Other: pharmacological study

First Posted Date: 2004-06-04

Last Posted Date: 2015-05-08

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 55

Registration Number: NCT00004146

Locations: 🇺🇸
University of Alabama Birmingham, Birmingham, Alabama, United States
🇺🇸
Moffitt Cancer Center, Tampa, Florida, United States
🇺🇸
Emory University/Winship Cancer Institute, Atlanta, Georgia, United States

and more 5 locations

Thalidomide in Treating Patients With Recurrent or Metastatic Head and Neck Cancer

Phase 2

Completed

Conditions: Head and Neck Cancer

Interventions: Drug: thalidomide

First Posted Date: 2004-06-03

Last Posted Date: 2013-02-08

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 47

Registration Number: NCT00003850

Locations: 🇺🇸
University of Texas - MD Anderson Cancer Center, Houston, Texas, United States

6-Hydroxymethylacylfulvene in Treating Patients With Refractory Myelodysplastic Syndrome, Acute Myeloid Leukemia, Acute Lymphocytic Leukemia, or Blastic Phase Chronic Myelogenous Leukemia

Phase 1

Completed

Conditions: Leukemia
Myelodysplastic Syndromes

Interventions: Drug: irofulven

First Posted Date: 2004-06-03

Last Posted Date: 2013-02-08

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 25

Registration Number: NCT00003997

Locations: 🇺🇸
University of Texas - MD Anderson Cancer Center, Houston, Texas, United States

Carboxyamidotriazole and Ketoconazole in Treating Patients With Advanced Cancers

Phase 1

Completed

Conditions: Unspecified Adult Solid Tumor, Protocol Specific

Interventions: Drug: carboxyamidotriazole
Drug: chemotherapy
Drug: ketoconazole

First Posted Date: 2004-06-03

Last Posted Date: 2013-02-07

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 30

Registration Number: NCT00003249

Locations: 🇺🇸
University of Chicago Cancer Research Center, Chicago, Illinois, United States

Genetic and Protein Profiling in Normal and Cancerous Breast Tissue

Completed

Conditions: Breast Neoplasms

First Posted Date: 2004-05-31

Last Posted Date: 2017-07-02

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 216

Registration Number: NCT00083733

Locations: 🇺🇸
National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, United States

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy